comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 21:34:56 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

hotspot

WSS

Baltimore teen accused of firing into crowd during block party mass shooting

NEJM study measures Covid brain fog, impact on IQ

The pain doctors face in trying to build their families

Laying a path for careers in science

CDC panel: People 65 and older should get a Covid spring booster shot

New details revealed about Purdue's marketing of OxyContin

hotspot

comprehensive

leisure time

Activists slam private health insurers over coverage restrictions

ActiGraph execs on goal of drug approvals with digital endpoints

Cancer drug shortages should be causing more outrage

Clinical trials must include more disabled people

BioMarin wins approval for gene therapy to treat hemophilia A

Liz Cheney makes 1st public comment since Trump's election interference indictments

Virginia high school admissions case could be legal follow

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Hepatitis C has a cure — but many Americans still lack access to it

As Maui death toll rises, number of missing remains unclear

entertainment

Trump's false claims about Georgia's 2020 election long debunked

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Childhood vaccination ad campaign launches in the U.K.

Cholera vaccine supplies dangerously low, outbreaks surging

New definition of a human embryo proposed amid rapid advances

Children’s Hospital revives plan for pedestrian bridge

entertainment

hotspot

focus

focus